Get the Stockscreener App
3.55
2.00%
0.05
After Hours:
3.50
-0.05
-1.41%
Sagimet Biosciences Inc stock is traded at $3.55, with a volume of 334.36K.
It is up +2.00% in the last 24 hours and up +3.48% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$3.50
Open:
$3.46
24h Volume:
334.36K
Relative Volume:
0.70
Market Cap:
$108.91M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-2.9933
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+3.48%
1M Performance:
+3.48%
6M Performance:
-37.26%
1Y Performance:
-33.89%
1-Day Range:
$3.32
$3.63
1-Week Range:
$3.32
$3.85
52-Week Range:
$1.73
$7.38
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
3.55 | 109.79M | 0 | -29.25M | -22.80M | -1.186 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment - Investing.com Australia
Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment By Investing.com - Investing.com Nigeria
Sagimet Biosciences to host KOL event on denifanstat, resmetirom - TipRanks
Sagimet Biosciences (SGMT) to Host Key Opinion Leader Event on I - GuruFocus
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating - GlobeNewswire
Leading MASH Expert to Present Groundbreaking Denifanstat-Resmetirom Combination Therapy Data - Stock Titan
Dimensional Fund Advisors LP Buys Shares of 25,334 Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
6,810 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by Wells Fargo & Company MN - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Wednesday - Defense World
Sagimet Biosciences Reports Q1 2025 Financial Results - MSN
Sagimet Biosciences, Inc.: A Promising Investment in the NASH Market with Strategic Growth Initiatives - TipRanks
Oppenheimer Revises Price Target for Sagimet Biosciences (SGMT) - GuruFocus
Oppenheimer Revises Price Target for Sagimet Biosciences (SGMT) | SGMT Stock News - GuruFocus
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Sagimet Biosciences Reports Q1 Financial Results and Updates - TipRanks
Renaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc (SGMT) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Take off with Sagimet Biosciences Inc (SGMT): Get ready for trading - Sete News
Sagimet Biosciences announces board change - Investing.com Australia
Geode Capital Management LLC Increases Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences announces board change By Investing.com - Investing.com Nigeria
Sagimet Biosciences Inc [SGMT] Investment Appeal on the Rise - knoxdaily.com
Sagimet Biosciences Inc (SGMT)’s stock chart: A technical perspective - uspostnews.com
Insider’s View: Deciphering Sagimet Biosciences Inc (SGMT)’s Financial Health Through Ratios - DWinneX
Sagimet Biosciences Inc [SGMT] Shares Rise 8.82 % on Wednesday - knoxdaily.com
What is Sagimet Biosciences Inc (SGMT) Stock Return on Shareholders’ Capital? - Sete News
Sagimet Biosciences (SGMT) to Present Denifanstat Study Findings at EASL 2025 | SGMT Stock News - GuruFocus
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 - GlobeNewswire
Breakthrough MASH Drug Shows Extended Phase 2b Results: 3 New Analyses Reveal Treatment Impact - Stock Titan
Sagimet Biosciences Inc (SGMT) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Predicting Sagimet Biosciences Inc’s (SGMT) earnings for the current quarter - uspostnews.com
SGMT’s Stock Market Adventure: -51.78% YTD Growth Amidst Volatility - investchronicle.com
20,103 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Purchased by American Century Companies Inc. - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Holdings of Sagimet Biosciences Inc (SGMT) are aligned with the stars - Sete News
SGMT’s Debt-to-Equity Ratio at 0.00: What It Means for Sagimet Biosciences Inc’s Future - investchronicle.com
Virtu Financial LLC Sells 9,123 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - The AM Reporter
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld MedTech
Sagimet Biosciences Inc. (SGMT) reports earnings - Quartz
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sagimet Biosciences Inc Stock (SGMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 19 '24 |
Sale |
3.10 |
8,357 |
25,910 |
81,213 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 19 '24 |
Sale |
3.10 |
10,914 |
33,830 |
160,506 |
| Kemble George | Executive Chairman |
Jul 19 '24 |
Sale |
3.10 |
14,062 |
43,605 |
142,318 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):